TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy
NCT04695327
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
BIOLOGICAL:
TILT-123
Sponsor
TILT Biotherapeutics Ltd.